Potential antitrust deregulation could foster a more favourable environment for larger M&A deals in 2025, though skepticism ...
Meanwhile, Lilly announced plans to acquire Scorpion Therapeutics’ PI3Kα inhibitor STX-478 for $2.5 billion, with its non-PI3Kα drugs spun off into a new company. STX-478 is currently in Phase ...
The pharma group did not break down the details of the license to get control of STX-478, described as a next-generation PI3K alpha inhibitor for breast cancer and other advanced solid tumours ...
Lilly’s bid to acquire Scorpion was driven by the Scorpion’s PI3Kα inhibitor program that is centered on the drug STX-478. The drug is in clinical studies evaluating its potential in solid tumours and ...
With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help ...
Lilly is taking the STX-478 program and then spinning it off into a new independent company, which will be owned by Scorpion’s current shareholders. Lilly will have a minority stake in the new ...
Eli Lilly and Scorpion Therapeutics announced a definitive agreement for Lilly to acquire Scorpion’s PI3Kalpha inhibitor program STX-478. STX-478 is a once-daily oral, mutant-selective PI3Kalpha ...
Relay Therapeutics (market cap: $748.2 million), a biotechnology company focused on developing innovative cancer therapies, ...
Key Takeaways JNJ will buy Intra-Cellular Therapies, producer of a drug for bipolar disorder, for $14.6 billion. Eli Lilly ...